Marshall Wace
CLDX icon

Marshall Wace’s Celldex Therapeutics CLDX Stock Holding History

Marshall Wace’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-276,728
Closed -$9.41M – 2618
2024
Q3 		$9.41M Sell
276,728
-1,101,140
-80% -$42M 0.01% 782
2024
Q2 		$51M Buy
1,377,868
+479,068
+53% +$18.1M 0.07% 256
2024
Q1 		$37.7M Sell
898,800
-381,284
-30% -$15.7M 0.06% 315
2023
Q4 		$50.8M Buy
1,280,084
+741,765
+138% +$21.8M 0.09% 231
2023
Q3 		$14.8M Buy
538,319
+248,796
+86% +$7.8M 0.03% 517
2023
Q2 		$9.82M Sell
289,523
-44,143
-13% -$1.49M 0.02% 734
2023
Q1 		$12M Sell
333,666
-333,083
-50% -$14.4M 0.03% 645
2022
Q4 		$29.7M Buy
666,749
+14,028
+2% +$501K 0.07% 334
2022
Q3 		$18.3M Buy
652,721
+632,698
+3,160% +$19.4M 0.04% 507
2022
Q2 		$539K Buy
+20,023
New +$581K ﹤0.01% 2756
2021
Q2 		– Sell
-20,580
Closed -$423K – 2698
2021
Q1 		$423K Buy
20,580
+8,557
+71% +$196K ﹤0.01% 2006
2020
Q4 		$211K Buy
+12,023
New +$216K ﹤0.01% 1737
2015
Q4 		– Sell
-7,207
Closed -$1.14M – 987
2015
Q3 		$1.14M Buy
+7,207
New +$2.04M 0.01% 603

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Marshall Wace's CLDX Position: Q4 2024 in Review

Marshall Wace sold out of Celldex Therapeutics (CLDX) in Q4 2024, closing a stake of 276,728 shares — an estimated $9.41M sold.

Marshall Wace first reported a position in CLDX in Q3 2015 and held it in 13 quarters. The position peaked at $51M in Q2 2024. 174 funds tracked by Wall St. Rank hold CLDX as of Q4 2024.

  • Marshall Wace reported no remaining Celldex Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Marshall Wace sold 276,728 Celldex Therapeutics shares in Q4 2024, an estimated $9.41M.
  • Marshall Wace first reported a position in Celldex Therapeutics in Q3 2015 and held it in 13 quarters.
  • Marshall Wace's Celldex Therapeutics position peaked at $51M in Q2 2024.
  • 174 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2024.

Based on Marshall Wace's 13F filing for Q4 2024, filed 13 Feb 2025.